Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study

Atherosclerosis

Volumn 255, Issue , 2016, Pages 193-199

  Waheed, Salman ^a,b   Pollack, Simcha ^a,c   Roth, Marguerite ^a   Reichek, Nathaniel ^a,d   Guerci, Alan ^a   Cao, Jie J ^a,d  

^a ST FRANCIS HOSPITAL   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c ST JOHN'S UNIVERSITY   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

Cardiovascular risk; Clinical risk profile; Coronary artery calcium; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; PLACEBO; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CONTROLLED STUDY; CORONARY ARTERY CALCIUM SCORE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; AGED; ASYMPTOMATIC DISEASE; BLOOD; COMORBIDITY; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIAS; KAPLAN MEIER METHOD; MORTALITY; MYOCARDIAL INFARCTION; NEW YORK; PATIENT SELECTION; PREDICTIVE VALUE; PREVALENCE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; TIME FACTOR; TREATMENT OUTCOME; VASCULAR CALCIFICATION;

AGED; ASYMPTOMATIC DISEASES; ATORVASTATIN CALCIUM; BIOMARKERS; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; NEW YORK; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PREVALENCE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR CALCIFICATION;

EID: 84999816188     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.09.060     Document Type: Article

References (23)

1. [1] Sangiorgi, G., Rumberger, J.A., Severson, A., et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J. Am. Coll. Cardiol. 31 (1998), 126–133.
2. [2] Becker, A., Leber, A.W., Becker, C., et al. Predictive value of coronary calcifications for future cardiac events in asymptomatic patients with diabetes mellitus: a prospective study in 716 patients over 8 years. BMC Cardiovasc. Disord., 8, 2008, 27.
3. [3] Budoff, M.J., Shaw, L.J., Liu, S.T., et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J. Am. Coll. Cardiol. 49 (2007), 1860–1870.
4. [4] Detrano, R., Guerci, A.D., Carr, J.J., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N. Engl. J. Med. 358 (2008), 1336–1345.
5. [5] Erbel, R., Mohlenkamp, S., Moebus, S., et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J. Am. Coll. Cardiol. 56 (2010), 1397–1406.
6. [6] Greenland, P., LaBree, L., Azen, S.P., Doherty, T.M., Detrano, R.C., Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 291 (2004), 210–215.
7. [7] Kondos, G.T., Hoff, J.A., Sevrukov, A., et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 107 (2003), 2571–2576.
8. [8] LaMonte, M.J., FitzGerald, S.J., Church, T.S., et al. Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women. Am. J. Epidemiol. 162 (2005), 421–429.
9. [9] Silverman, M.G., Blaha, M.J., Krumholz, H.M., et al. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis. Eur. Heart J. 35 (2014), 2232–2241.
10. [10] Nasir, K., Rubin, J., Blaha, M.J., et al. Interplay of coronary artery calcification and traditional risk factors for the prediction of all-cause mortality in asymptomatic individuals. Circ. Cardiovasc. Imaging 5 (2012), 467–473.
11. [11] Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 63 (2014), 2889–2934.
12. [12] Pursnani, A., Massaro, J.M., D'Agostino, R.B. Sr., O'Donnell, C.J., Hoffmann, U., Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA 314 (2015), 134–141.
13. [13] Nasir, K., Bittencourt, M.S., Blaha, M.J., et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 66 (2015), 1657–1668.
14. [14] Arad, Y., Newstein, D., Roth, M., Guerci, A.D., Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification. Control. Clin. Trials 22 (2001), 553–572.
15. [15] Arad, Y., Spadaro, L.A., Roth, M., Newstein, D., Guerci, A.D., Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J. Am. Coll. Cardiol. 46 (2005), 166–172.
16. [16] Agatston, A.S., Janowitz, W.R., Hildner, F.J., Zusmer, N.R., Viamonte, M. Jr., Detrano, R., Quantification of coronary artery calcium using ultrafast computed tomography. J. Am. Coll. Cardiol. 15 (1990), 827–832.
17. [17] Newson, R.B., Comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata J. 10 (2010), 339–358.
18. [18] Pencina, M.J., D'Agostino, R.B. Sr., D'Agostino, R.B. Jr., Vasan, R.S., Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 27 (2008), 157–172 discussion 207–12.
19. [19] StataCorp LP. Statistics/Data Analysis. 4905 Lakeway Drive CS, TX.
20. [20] Kiramijyan, S., Ahmadi, N., Isma'eel, H., et al. Impact of coronary artery calcium progression and statin therapy on clinical outcome in subjects with and without diabetes mellitus. Am. J. Cardiol. 111 (2013), 356–361.
21. [21] DeFilippis, A.P., Blaha, M.J., Ndumele, C.E., et al. The association of Framingham and Reynolds risk scores with incidence and progression of coronary artery calcification in MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 58 (2011), 2076–2083.
22. [22] Mulders, T.A., Sivapalaratnam, S., Stroes, E.S., Kastelein, J.J., Guerci, A.D., Pinto-Sietsma, S.J., Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study. JACC Cardiovasc. Imaging 5 (2012), 252–260.
23. [23] Budoff, M.J., Nasir, K., McClelland, R.L., et al. Coronary calcium predicts events better with absolute calcium scores than age-sex-race/ethnicity percentiles: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 53 (2009), 345–352.